Silodosin in Management of Lower Ureteral Stones

This research aims to study the effectiveness of silodosin in the management of lower ureter stones larger than 6 mm in diameter in terms of affected ureter (right or left), the size of the stone, the degree of hydronephrosis, the rate of stone expulsion(day), whether the stone was completely expelled or not, and the side effects of silodosin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stone, Kidney Calculi Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Calculi Kidney Diseases Male Urogenital Diseases Nephrolithiasis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Urinary Calculi Urogenital Diseases Urolithiasis Urologic Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Damascus university

Damascus, 1, Syria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients attending the urology Clinic with a distal unilateral ureteral stone larger than 6 mm in diameter.

Exclusion criteria

Patients under 18 years of age
Pregnant women
Patients with whom we were unable to contact
Patients treated with silodosin for another reason
Single kidney patients
Patients with bilateral ureter stones
Patients with deteriorating kidney function
Patients with grades 3rd and 4th of hydronephrosis

Treatment and study plan

Silodosin

Drug

Selective Alpha Blocker drug

Primary outcomes

Stone expulsion (yes)

Time frame: 1 year

patients who were able to expel the stone
Stone expulsion (no)

Time frame: 1 year

patients who were not able to expel the stone

Sponsors and collaborators

Lead sponsor

Syrian Private University

Other

Registry information

Official study title

The Use of Selective Alpha Blockers (Silodosin) in Management of Lower Ureteral Stones Larger Than 6 mm in Diameter

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Apr 24, 2024
Registry last updated: Apr 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed